Australia, July 14 -- Clarity Pharmaceuticals Ltd., owns the trademark (2448498) for 'CLARITY PHARMACEUTICALS' and 'DISC BELOW WAVY STRIPE THRU POLYGON' till May 7, 2034.
Status: registered:
Registered/protected
Classes: 1 [Radioactive substances for scientific and commercial purposes; chemical products for industrial, scientific and research purposes; chemical reagents and preparations for industrial, scientific and research purposes; fissionable chemical elements; radioactive elements and isotopes for industrial, scientific and research purposes; radioactive preparations for commercial purposes, namely nuclides and radionuclides, radioactive and radiographic sources as well as radioactive sources and compounds for use in radiographic techniques for scientific purposes; radioactive standard preparations for the calibration of apparatus and machinery; chemical reagents for use with the aforesaid goods; all the aforesaid goods, insofar as they are included in this class; diagnostic preparations, other than for medical or veterinary purposes; isotopes for industrial purposes; radioactive elements for scientific purposes; radioactive preparations for scientific purposes; chemical reagents (other than for medical or veterinary purposes); chemicals for use in the manufacture of radiopharmaceutical products; chemical products for radioactive labelling; radiodiagnostic in-vivo means for scientific purposes; radiochemical products for scientific purposes; radioactive materials for laboratory purposes; radioactive materials for scientific purposes; chemical products for laboratory analyzes (except for medical or veterinary purposes)], 5 [Pharmaceutical, medicinal, veterinary and therapeutic preparations and substances; pharmaceutical preparations and substances for diagnosis; pharmaceutical preparations and substances for therapy and treatment; pharmaceutical, medicinal, veterinary and therapeutic preparations and substances for theranostics; pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances; radiopharmaceuticals; radioprotectors for medical use; radiopharmaceuticals for use in theranostics; radiopharmaceutical products; radiopharmaceutical diagnostic and therapeutic preparations for medical purposes; radiopharmaceuticals for medical and clinical use; radiopharmaceutical sources and norms for nuclear medicine; radiopharmaceutical preparations and substances for use in oncology, namely radiopharmaceuticals for diagnosing and treating cancer; radiopharmaceuticals, particularly for the treatment of cancer; radio therapeutic preparations; chemical substances and preparations being radioactive substances for medical purposes; radioisotopes for medical purposes; diagnostic and therapeutic radioisotopes and radiochemicals for medical purposes; radiopharmaceutical preparations and substances for endo-radionuclide therapy, brachytherapy; radiopharmaceuticals used in the field of nuclear medicine, medical imaging and therapy; radiopharmaceutical preparations and substances for positron emission tomography; radiopharmaceutical preparations and substances for single photon emission tomography, target radionuclide and peptide receptor radionuclide therapy; theranostics in the field of oncology; theranostics in the field of precision oncology; radiopharmaceutical preparations for use in oncology, namely radiopharmaceuticals containing radioisotopes for treatment and diagnosis of tumours; target radiopharmaceuticals containing a target molecule; preparations for targeted radionuclide therapy; therapeutic agents for delivery of radioactive material to target sites within the body; irradiated or radioactive microspheres used for therapeutic medical purposes; radiopharmaceuticals for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; radiopharmaceuticals containing radioisotopes with short half-lives for diagnostic applications; chemicals for pharmaceutical use; chemicals for radiopharmaceuticals for diagnostic uses; pharmaceutical drugs; pharmaceutical preparations for the treatment of cancer; radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as positron emission tomography or single photon emission tomography, for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, for the treatment of tumour diseases; chemicals for radiopharmaceuticals for diagnostic uses; radiopharmaceutical drugs for diagnostic uses; radiopharmaceutical preparations for diagnostic uses; radiopharmaceutical products for diagnostic uses; radioactive pharmaceutical preparations; radioactive elements, isotopes, preparations and reagents for radioactive labelling of pharmaceutical products; radioactive pharmaceuticals and non-radioactive reagents for producing radiopharmaceuticals for diagnosis or for therapeutic use; implantable radiotherapy preparations; diagnostic agents, preparations and substances for medical purposes; diagnostic scanning agents for medical use; positron emission tomography tracers for medical use (pharmaceutical preparations); positron emission tomography tracers prepared for ingestion or injection into humans and animals (pharmaceutical preparations); reagents for medical purposes; preparations for use in molecular imaging (for medical use); radiotherapeutic preparations; radiodiagnostic preparations; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of disease; radioactive marked substances for diagnostic purposes; radiopharmaceuticals and radioactive marked substances for therapeutic purposes; solutions for radioactive labelling; diagnostic preparations and reagents for medical use; diagnostic substances for medical use; contrasting substances for medical imaging; scanning diagnostic reagents; diagnostic imaging agents for magnetic resonance imaging; diagnostic and therapeutic chemicals for medical purposes], 6 [Containers of metal for storage, transport and packaging; containers of metal for storing and transporting radioactive elements, products and materials; containers of metal for storing and transporting radioactive products; containers of metal for storing and transporting medical goods, apparatus and devices; containers of metal for storing and transporting radiopharmaceuticals, pharmaceuticals, medical goods, apparatus and devices for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; parts and fittings for the aforesaid goods], 10 [Radiotherapy apparatus and instruments; implantable radioactive sources of radiation; instruments and apparatus for immunotherapy and immuno-diagnostics; radiodiagnostic devices for medical purposes; medical apparatus and instruments, namely for the manufacture of radionuclides; radiological apparatus for medical purposes; storage and transport containers for protection against ionising radiation for medical use; insulated containers for temperature sensitive products for medical use, namely, insulated containers designed for transporting and holding radiopharmaceuticals; temperature controlled packaging specifically adapted for the transportation of radiopharmaceuticals; refrigerated medical containers for storage, transportation and cooling of radiopharmaceuticals; devices for detecting ionising radiation for medical use; radiation therapy equipment; radioisotope apparatus for medical purposes; radio-oncological irradiation apparatus for medical purposes; radio oncological irradiation instruments for medical purposes; linear accelerator for medical purposes in radiotherapy; apparatus and instruments for radioisotopic therapy; radiation therapy instruments for medical purposes; medical devices for dosimetry in the field of radiotherapy; nuclear medical tomographic scanner; diagnostic imaging apparatus for nuclear medicine; cancer irradiation apparatus for medical purposes; cancer irradiation instruments for medical purposes; apparatus for administering radiopharmaceuticals; apparatus for the treatment of cancer; radiodiagnostic imaging apparatus for medical use; radiopharmaceutical instruments; applicators for radiopharmaceutical preparations; medical apparatus kits for preparing radiodiagnostic imaging agents; medical apparatus for administering radiopharmaceutical diagnostic products; containers of metal for medical waste; non-metallic containers for medical waste; non-metallic containers for storing and transporting medical goods, apparatus and devices; non-metallic containers for storing and transporting radiopharmaceuticals, pharmaceuticals, medical goods, apparatus and devices for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; parts and fittings for the aforesaid goods], 20 [Non-metallic containers; non-metallic containers for storing and transporting radioactive elements, products and materials; non-metallic containers for storing and transporting radioactive products; structural foam containers for storage or transport; containers for transport, not of metal; parts and fittings for the aforesaid goods], 35 [import, export, sale, supply and distribution (of advertising materials and samples) services of theranostic and radiopharmaceuticals; disseminating business, consumer, or commercial information in the field of theranostic and radiopharmaceuticals; providing an on-line commercial information directory for products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; information, support, assistance, consultancy and advisory services in relation to the aforementioned services], 39 [Supply chain logistics and reverse logistics services consisting of the storage, transportation and delivery of goods; supply chain, logistics and reverse logistics services namely the storage, transportation and delivery of pharmaceuticals, radiopharmaceuticals, pharmaceutical and radiopharmaceuticals products for others by air, rail, ship or truck; packaging of clinical, pharmaceutical, radiopharmaceutical and health care products to the order and specification of others; leasing of temperature controlled cases for storage and transportation purposes; rental of insulated shipping containers for transporting temperature controlled materials; rental of insulated shipping containers for transporting room temperature, chilled, and frozen materials; information, support, assistance, consultancy and advisory services in relation to the aforementioned services], 40 [Custom manufacture of pharmaceuticals; custom manufacture of pharmaceuticals for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; custom manufacture of radiopharmaceuticals; custom manufacture of radiopharmaceuticals for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; custom manufacture of radioprotectors; custom manufacture of radiotherapy apparatus, devices and instruments; custom manufacture of apparatus, devices and instruments for medical purposes; custom manufacture of apparatus, devices and instruments for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; information, support, assistance, consultancy and advisory services in relation to the aforementioned services], 42 [Pharmaceutical, medicinal, veterinary and therapeutic research and development in connection with the fields of medical imaging, theranostics, oncology, and nuclear medicine; pharmaceutical, medicinal, veterinary and therapeutic research and development in relation to radiopharmaceuticals for use in the imaging, diagnosis, treatment and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; clinical trials in relation to radiopharmaceuticals for use in the imaging, diagnosis, treatment and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; scientific research and development in the field of radiopharmaceuticals and radioprotectors; scientific research and development in the field of theranostics; scientific research and development in the field of radioisotopes suitable for diagnostic and therapeutic medical use; scientific and technological services and research on radiopharmaceuticals for the diagnosis, therapy and treatment of diseases; scientific research and development of new procedures and experiments for the discovery, identification or improvement of radioisotopes for medical use; engineering services in the field of radiopharmaceuticals and radioisotopes suitable for diagnostic and therapeutic and medical use; scientific research and development of radioisotopes suitable for radiopharmaceuticals; scientific research and development of new procedures and experiments for the discovery, identification or improvement of radioisotopes for radiopharmaceuticals; scientific research and development and engineering services in the field of radioisotopes, radioisotope generators, and linkers suitable for radiopharmaceuticals; scientific research and development in the isolation and capture of radioisotopes suitable for radiopharmaceuticals; conducting clinical trials at all stages and in various indications, particularly in oncology; conducting phase clinical trials with target radiopharmaceuticals; medical and scientific research, namely, conducting clinical and pre-clinical trial services for others in connection with the fields of medical imaging, theranostics, oncology, and nuclear medicine; pharmaceutical research and development services in connection with the fields of medical imaging, theranostics, oncology, and nuclear medicine; testing of pharmaceutical pharmacodynamics, pharmacokinetics and efficacy using a variety of imaging modalities and imaging analysis platforms in connection with the fields of medical imaging, theranostics, oncology, and nuclear medicine; medical radio imaging services and pathology in support of pharmaceutical research and development; theranostic and oncological drug discovery services; conducting early evaluations in the field of new theranostic and oncological drugs; scientific investigations for medical research purposes in connection with the fields of medical imaging, theranostics, oncology, and nuclear medicine; medical and scientific research laboratory services in the fields of radiopharmaceuticals and radioprotectors; medical and scientific research, namely, providing analysis of medical radio imaging data obtained from pre-clinical and clinical trial studies; medical and scientific research in the fields of medical radiology imaging, pathology and digital pathology; providing medical and scientific research information in the fields of radiopharmaceuticals; research and development in the fields of medical imaging and, radiopharmaceuticals and biotechnology; research services in the fields of magnetic resonance and molecular imaging; medical research services relating to the development of radiotherapeutics and precision oncology; pathology services in support of theranostic and oncological drug development; pathology services for preclinical biomarker discovery research and clinical trials in connection with the fields of medical imaging, theranostics, oncology, and nuclear medicine; imaging contract research organization services and technology solutions, namely, imaging services for medical and scientific research purposes and technology solutions, namely, reviewing of radiology images throughout the clinical trial process and blind independent central review of radiology images in the medical research and clinical trial setting; development and evaluation of radiodiagnostic imaging biomarkers for clinical trial purposes; radiochemistry services; research, development and testing services relating to radiopharmaceuticals; radio labelling scientific research, namely, labelling of both small molecules and biologics; research and development of radiopharmaceuticals; scientific and medical research and product design in relation to positron emission tomography imaging; scientific and medical research and product design in relation to single photon emission tomography imaging; design and development of containers for the storage and transport of radioactive materials, radiopharmaceuticals, pharmaceuticals, medical goods, apparatus and devices for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; scientific and medical research in relation to molecular imaging; development of molecular imaging products, development of non-medical molecular imaging services; diagnostic imaging for scientific research purposes; information, advisory and consultancy services in relation to the aforementioned services] and 44 [provision of medical, health care and wellness (health and nutrition advice) services in relation to the prevention, treatment, prophylaxis and management of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; medical counselling services in the field of treatment, prophylaxis or prevention of oncological conditions; information, support, assistance, consultancy and advisory services in relation to the aforementioned services]
Type of Mark: Figurative
Date of Acceptance: May 5
Registration Advertised: July 13
For further details contact Davies Collison Cave Pty. Ltd. .
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2448498.
Disclaimer: Curated by HT Syndication.
